Aclarion, Inc. (ACON) - 10-K Filing Summary
Business Context and Reporting Period
Company: Aclarion, Inc.
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: Aclarion is a healthcare technology company developing the NOCISCAN platform, which uses Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to non-invasively identify painful intervertebral discs in patients with chronic low back pain. The company operates in a single segment and is classified as an "emerging growth company" and a "smaller reporting company."
Operational Status: The company has limited commercial sales to date, primarily relying on patient-pay models and clinical studies. It is actively seeking third-party payer contracts for its Category III CPT codes to drive commercialization.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $46 | $75 |
| Cost of Revenue | $85 | $76 |
| Gross Profit (Loss) | $(39) | $(0.3) |
| Operating Expenses | $5,474 | $4,876 |
| Net Loss | $(6,993) | $(4,911) |
| Cash and Cash Equivalents (Year End) | $454 | $1,021 |
| Accumulated Deficit | $(51,262) | $(44,282) |
Note: Revenue figures are rounded to the nearest thousand. The company reported a net loss per share of $(7,480) for 2024 (post-split adjusted).
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 39% (from $75,404 to $45,724) due to reduced utilization in third-party clinical studies, partially offset by an increase in patient-pay volumes.
- Increased Losses: Net loss increased by 42% to $6.99 million, driven by higher operating expenses and significant non-cash charges related to debt exchanges.
- Debt Restructuring: The company retired all outstanding notes payable during 2024 through cash payoffs and exchanges for common and preferred stock. This resulted in a $1.07 million loss on the exchange of debt and a $212,453 charge for penalties and settlements.
- Expense Growth: Sales and marketing expenses rose 29% due to the initiation of the Clarity clinical study. General and administrative expenses increased 11% due to investor relations services and equity line costs.
- Stock Splits: The company effected a 1:16 reverse stock split in January 2024 and two subsequent reverse stock splits in 2025 (1:335 and 1:27) to regain Nasdaq compliance. All share data in this summary is adjusted for these splits.
Guidance, Outlook, and Risks
Liquidity and Capital Resources: As of December 31, 2024, the company held approximately $0.46 million in cash. Management believes current resources, combined with $20.1 million raised in subsequent events (January 2025 public offering and registered direct offerings), will fund operations into the third quarter of 2026. The company expects to continue incurring significant losses as it scales commercialization.
Outlook and Strategy: The primary near-term strategy is securing payer contracts for Category III CPT codes. The company is expanding scanner compatibility (engaging Philips in Q1 2025) and building clinical registries to support the conversion of temporary codes to permanent Category I codes.
Material Risks and Contingencies:
- Going Concern: Auditors previously expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and working capital deficiencies, though recent capital raises have mitigated immediate risk.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting related to segregation of duties and lack of adequate accounting resources for complex transactions.
- Regulatory Compliance: The company faces risks regarding FDA classification of its software (NOCIGRAM) and EU Medical Device Regulation (MDR) compliance, which may require re-certification by a Notified Body.
- Intellectual Property: The business relies heavily on an exclusive license from the Regents of the University of California; termination of this license would materially harm operations.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $20.1 million raised in early 2025 to cover the projected burn rate through Q3 2026.
- Reimbursement Progress: Monitor the conversion of Category III CPT codes to Category I and the status of payer coverage decisions.
- Internal Controls: Review subsequent filings for remediation of the identified material weaknesses in financial reporting.
- Regulatory Status: Confirm the status of EU MDR re-certification and FDA classification of the NOCIGRAM software.
- Stock Split Impact: Ensure all share counts and per-share metrics are reviewed with the 2024 and 2025 reverse stock splits in mind.